title: Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study.
abstract: OBJECTIVE
  To compare the efficacy and safety of famciclovir with aciclovir for the treatment of ophthalmic zoster.
  
  
  METHODS
  Randomised, double masked, aciclovir controlled, parallel group in 87 centres worldwide including 454 patients with ophthalmic zoster of trigeminal nerve (V(1)) comprised the intent to treat population. Oral famciclovir 500 mg three times daily or oral aciclovir 800 mg five times daily for 7 days. Assessments included day 0 (screening), days 3 and 7 (during treatment), days 10, 14, 21, 28 and monthly thereafter, up to 6 months (follow up). Proportion of patients who experienced ocular manifestations, severe manifestations and non-severe manifestations; loss of visual acuity was the main outcome measure.
  
  
  RESULTS
  The percentage of patients who experienced one or more ocular manifestations was similar for famciclovir (142/245, 58.0%) and aciclovir (114/196, 58.2%) recipients, with no significant difference between groups (OR 0.99; 95% CI 0.68, 1.45). The percentage of patients who experienced severe and non-severe manifestations was similar between groups, with no significant difference. The prevalence of individual ocular manifestations was comparable between groups. There was no significant difference between groups for visual acuity loss.
  
  
  CONCLUSIONS
  Famciclovir 500 mg three times daily was well tolerated and demonstrated efficacy similar to aciclovir 800 mg five times daily.
authors.affiliation: University of Texas Medical Branch, Galveston, TX, USA.
authors.forename: S
authors.initials: S
authors.lastname: Tyring
authors.forename: R
authors.initials: R
authors.lastname: Engst
authors.forename: C
authors.initials: C
authors.lastname: Corriveau
authors.forename: N
authors.initials: N
authors.lastname: Robillard
authors.forename: S
authors.initials: S
authors.lastname: Trottier
authors.forename: S
authors.initials: S
authors.lastname: Van Slycken
authors.forename: R A
authors.initials: RA
authors.lastname: Crann
authors.forename: L A
authors.initials: LA
authors.lastname: Locke
authors.forename: R
authors.initials: R
authors.lastname: Saltzman
authors.forename: A G
authors.initials: AG
authors.lastname: Palestine
mesh_terms: D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000212:Acyclovir / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use*; D016001:Confidence Intervals; D004311:Double-Blind Method; D000077595:Famciclovir; D005260:Female; D006563:Herpes Zoster Ophthalmicus / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D000998:Antiviral Agents; D015075:2-Aminopurine; D000077595:Famciclovir; D000212:Acyclovir